English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In 2007, the University of British Columbia (UBC) unveiled a new licensing strategy to promote developing world access to its technologies [1]. UBC's “Global Access License Principles” aim to ensure that the university's biotechnology and environmental licensees develop and market UBC-derived technologies for global benefit. Shortly thereafter, UBC licensed rights to commercialize a low-cost, oral formulation of Amphotericin B developed by Dr. Kishor M. Wasan. It was the first technology licensed under the new policy. In addition to its improved ease of administration and reduced toxicity when used as an antifungal agent, Dr. Wasan's oral Amphotericin B is also a novel agent against leishmaniasis. In return for rights to market the drug for the treatment of blood-borne fungal infections in the developed world, iCo Therapeutics agreed to produce and sell at-cost versions of the drug for treatment of leishmaniasis in developing countries.

The Silent Epidemic of Exclusive University Licensing Policies on Compounds for Neglected Diseases and Beyond